Navigation Links
Human Pheromone Sciences Announces Quarterly and Full Year Results

SAN JOSE, Calif., March 31, 2008 /PRNewswire-FirstCall/ -- Human Pheromone Sciences, Inc. (OTC Bulletin Board: EROX) ("HPS" or "the Company") today announced results for the three months and the year ended December 31, 2007. For the three months ended December 31, 2007, net revenue was $389,000, representing a 6% decrease from revenues of $412,000 in the prior year period, and resulted in net income of $38,000 ($.01 per share) as compared with a net income of $66,000 ($.02 per share) for the same period of 2006. For the full year, net revenues of $1,291,000, were 5% higher than revenues of $1,227,000 generated in the prior year. The net loss in the current year of $16,000 ($.00 per share) was a reduction from the $111,000 loss ($.03 per share) recorded for the full year of 2006.

"In the third and fourth quarters of 2006, we had very large orders from our largest purchaser of pheromones that were not replicated in the current year quarters. As such, for the full year, revenue from pheromone sales were $207,000 (24%) lower than in 2007, while revenues attributable to licensing activities rose by $344,000 (188%) from the prior year. The growth in total revenues in the current year is attributable to the licensing activities. Lower operating expenses, coupled with the revenue growth, gave rise to the improved bottom line in the current year," a spokesperson indicated.

"These cyclical pheromone purchases are unpredictable and, as such, we developed a set of strategic imperatives to grow our licensing revenues, to formulate a program to maximize revenues from our proprietary Natural Attractions(R) brand and to complete human testing on additional novel compounds that can contribute to the expansion of our business through the scientific validation of additional technologies that will enhance the value of our Company," a spokesman noted. "While we are not pleased by the financial results for the current year fourth quarter as compared with the prior year three month period, we believe that focus on these three strategic imperatives will lessen our dependence on the purchasing pattern of one large customer, and ensure balanced growth in revenue and an expanded technology and customer base, without major capital investment," the spokesman further noted.

Human Pheromone Sciences, Inc. is a technology-based company, whose proof-of-concept products included prestige-priced fragrances and toiletries and environmental products sold under the REALM(R), innerREALM(R) and EROX(R) trademarks. These products, and its Natural Attraction(R) product line, contain mood-enhancing synthesized human pheromones covered under U.S. and foreign patents. The Company also licenses its proprietary technology to other companies for inclusion in their products for direct sale to the consumer. Scientific and consumer studies have shown that the Company's human pheromones positively impact on the moods, attitudes and emotions of wearers. Further information is available on line at

The statements in this news release may contain forward-looking statements that involve risks and uncertainties that could cause results to differ from predicted results. Further information on factors that could affect the Company's results is detailed in the Company's annual report to shareholders on Form 10-KSB for the year ended December 31, 2007 as filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements.


Condensed Balance Sheets

(Dollars in thousands)

December 31, December 31,

2007 2006


Cash and cash equivalents $1,437 $1,941

Accounts receivable 194 39

Inventories, net 25 75

Other current assets 40 18

Property and equipment, net 3 2

Total $1,699 $2,075

Liabilities and Shareholders' Equity

Accounts payable $28 $30

Other current liabilities 141 114

Deferred income - current 518 846

Deferred income - non-current 566 721

Common stock 20,963 20,865

Accumulated deficit (20,517) (20,501)

Total $1,699 $2,075


Condensed Statements of Operations

(Dollars in thousands, except per-share data)

Three months Year

ended December 31, ended December 31,

2007 2006 2007 2006

Net revenues $389 $412 $1,291 $1,227

Cost of goods sold 99 108 376 287

Research and development 11 14 49 102

Selling, general and

administrative 256 235 942 969

Income (loss) from operations 23 55 (76) (131)

Other income 15 18 65 27

Income (loss) before provision

for income taxes 38 73 (11) (104)

Provision for Income taxes - 7 5 7

Net income (loss) $38 $66 $(16) $(111)

Net income (loss)

per share -

Basic $0.01 $0.02 $(0.00) $(0.03)

Fully diluted $0.01 $0.01 $(0.00) $(0.03)

Weighted average number

of shares -

Basic 4,152 4,152 4,152 4,152

Fully diluted 4,852 4,782 4,152 4,152

Net income (loss) per share is based on the weighted average number of common shares and common equivalents outstanding during each period. Certain common stock equivalents are excluded when their effect would be anti-dilutive.

SOURCE Human Pheromone Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources
Post Your Comments:
(Date:11/26/2015)... England , November 26, 2015 ... innovative medical device company specializing in imaging technologies, announced today ... European Commission as part of the Horizon 2020 European Union ... carry out a large-scale clinical trial in breast cancer. ... (Logo: , --> --> ...
(Date:11/25/2015)... and HOLLISTON, Mass. , Nov. 25, ... HART ), a biotechnology company developing bioengineered organ ... Jim McGorry will present at the LD Micro ... at 2:30 p.m. PT. The presentation will be webcast ... days. Management will also be available at the conference ...
(Date:11/25/2015)... 2015 The Global Genomics ... professional and in-depth study on the current state ... ) , The report ... definitions, classifications, applications and industry chain structure. The ... markets including development trends, competitive landscape analysis, and ...
(Date:11/24/2015)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. ... will provide a corporate overview. th Annual Oppenheimer ... p.m. ET/10:00 a.m. PT . Jim Mazzola , vice ... overview. --> th Annual Oppenheimer Healthcare Conference in ...
Breaking Biology Technology:
(Date:10/29/2015)... 29, 2015  Rubicon Genomics, Inc., today announced ... of its DNA library preparation products, including the ... ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has been optimized ... NGS libraries for liquid biopsies--the analysis of cell-free ... applications in cancer and other conditions. Eurofins Scientific ...
(Date:10/29/2015)... OXFORD, Connecticut , October 29, 2015 /PRNewswire/ ... "Company"), a biometric authentication company focused on the ... Wocket® smart wallet announces that StackCommerce, a leading ... will be featuring the Wocket® smart wallet on ... NXTD ) ("NXT-ID" or the "Company"), a ...
(Date:10/27/2015)... 27, 2015 In the present market scenario, ... for various industry verticals such as banking, healthcare, defense, ... growing demand for secure & simplified access control and ... as hacking of bank accounts, misuse of users, , ... as PC,s, laptops, and smartphones are expected to provide ...
Breaking Biology News(10 mins):